Open AccessPALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients
Author(s) -
Hiroji Iwata,
Seock Ah Im,
Norikazu Masuda,
Young Hyuck Im,
Kentaro Inoue,
Yoshiaki Rai,
Rikiya Nakamura,
Jee Hyun Kim,
Justin Hoffman,
Ke Zhang,
C. Giorgetti,
Shrividya Iyer,
Patrick Schnell,
Cynthia Huang Bartlett,
Jungsil Ro
Publication year - 2017
Publication title -
journal of global oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.002
H-Index - 17
ISSN - 2378-9506
DOI - 10.1200/jgo.2016.008318
Subject(s) - fulvestrant , palbociclib , medicine , metastatic breast cancer , oncology , breast cancer , neutropenia , placebo , cancer , anastrozole , hazard ratio , estrogen receptor , chemotherapy , confidence interval , tamoxifen , pathology , alternative medicine
To assess efficacy and safety of palbociclib plus fulvestrant in Asians with endocrine therapy-resistant metastatic breast cancer.